Algemeen Ziekenhuis Groeninge — Clinical Trial Site

165 Registered trials

70 Currently recruiting

Organisation

Algemeen Ziekenhuis Groeninge

Location

Kortrijk, Belgium

Identifier

ORG-100040919

Address

President Kennedylaan 4, 8500, Belgium

Departments

#1000: Cardiology
#3061: Cardiology
#40576: Memory Clinic
0501 Urologie
0504: Dept of Anesthesia
304: Nefrologie, dialyse
3061:Cardiology
7109: Cardiologie
Algologie
Anaesthesia & intensive care
Anesthesiologie
BE10002: Oncology
BEL005: Pulmonology
Campus Kennedylaan
Cardiology
centrum neurologie
Departement of Hematology
Department of Gastroenerology
Department of Medical Oncology
Department of Oncology
Department Urology
Digestive Oncology
Endocrinologie
Endocrinologie - Diabetologie
Endocrinology
Gastro-enterologie
Gastro-enterology
Gastroenterologie
Gastroenterologist
Gastroenterology
Hematologie
Hematology
Hemotologie
Internal Medicine
Kankercentrum: medische oncologie
Longziekten
Maag-Darm-Leverziekten
Medical Oncology
Medicine Oncology
N/A
NA
Nephrology
Neurologie
Neurology
Neurology Department
Oncologie médicale/ Medical Oncology
Oncologisch centrum
Oncology
Oncology Center
Pneumolgy
Pneumology
pneumology/allergy
Pulmonogy deparmtent
Pulmonology
Radiotherapie
Radiotherapy
Radiotherapy-Oncology
Respiratory Oncology / Pneumology
Rheumatology
Thoracic & vascular surgery
Thoracic and vascular surgery
Urologie
Urology

Clinical trials at this site (165)

Search interface

Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting

2024-511884-27-00 CD205+ve recurrent and/or metastatic tumor types includ 3 2022-11-09
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting

2023-508389-13-00 Combined endpoint of all-cause mortality, kidney failur 5 2022-11-08
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting

2023-503442-30-00 Multiple Myeloma 5 2022-10-14
Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio… Recruiting

2022-500311-39-00 Patients with Crohn's disease undergoing surgery and ha 6 2022-09-08
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting

2022-502373-42-00 Oligorecurrent hormone-sensitive prostate cancer patien 5 2022-04-25
GROINSS-V III Recruiting

2023-508722-99-00 Vulvar cancer 4 2020-11-19
ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting

2023-506857-40-00 Prostate Cancer 5 2019-01-08
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Ended

2024-511016-25-00 Chronic hepatitis B infection 4 2025-01-15
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
A Phase 2 Study of an Anti-MTBR Tau Monoclonal Antibody in Participants with Early Alzheimer’s Disease Ended

2023-504840-32-00 Early Alzheimer’s Disease 4 2024-11-08
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended

2024-511038-11-00 advanced prostate cancer 4 2024-09-24
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT … Ended

2023-508130-33-00 ADVANCED OR METASTATIC BREAST CANCER 9 2024-07-03
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w… Ended

2024-512023-37-00 Prostate cancer 4 2024-06-27
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab… Ended

2022-502954-15-00 Idiopathic pulmonary fibrosis 4 2024-06-21
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended

2023-509026-21-00 severe asthma 6 2024-06-03
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small… Ended

2023-506008-20-00 Extensive-stage small cell lung carcinoma (ES-SCLC) 3 2024-01-11
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18